Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in Coronary Atherosclerosis
NCT05071417Phase 3Not yet recruiting
- Sponsor
- Fundación Instituto de Ciencias de la Salud de Castilla y León
- Start
- Nov 2021
- Primary completion
- Dec 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of semaglutide in Coronary atherosclerosis (CAD), sponsored by Fundación Instituto de Ciencias de la Salud de Castilla y León. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
03
Conditions
Coronary atherosclerosis (CAD)
Beyond the preview
Go deeper on NCT05071417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05071417.